2024
conference-abstract
OpenAlex
Ashish Bino George, Shiker Nair, Mustafa Kocak, Ellen Nguyen et autres
Abstract Combination therapies are crucial in cancer care, yet identifying which combination will benefit a specific patient is challenging. The vast array of clinical, investigational, and tool anticancer agents and diverse cancer contexts makes investigating many drug combinations over a large number …
us
(code pays fourni par la source)
2024
conference-abstract
OpenAlex
Matthew G. Rees, Mustafa Kocak, Claudine Mapa, Dennie Tompers Frederick et autres
Abstract Cancer treatment options are rapidly expanding, with many new targeted agents and therapeutic modalities under development. However, systematic characterization of the cellular effects of emerging drug candidates is limited. Screening such agents against the approximately 900 diverse cancer cell lines in …
us
(code pays fourni par la source)
2024
conference-abstract
OpenAlex
Melissa M. Ronan, Blanche C. Ip, Ellen Nguyen, Ursula Widocki et autres
Abstract PRISM (Profiling Relative Inhibition Simultaneously in Mixtures), using DNA-barcoded cell lines cultured as ~25 cell line pools, has been an effective drug discovery screening platform to rapidly test large numbers of potential therapeutics on over 900 different cancer cell lines. However, …
us
(code pays fourni par la source)
2023
conference-abstract
OpenAlex
Jillian N. Eskra, Ellen Nguyen, Aydin Golabi, Shiker Nair et autres
Abstract Antibody-drug conjugates (ADCs) are a rapidly emerging class of cancer therapeutics composed of an antibody scaffold, a cytotoxic payload, and a joining linker. They exhibit properties of both biologics and small molecule inhibitors, can exert activity through multiple mechanisms, and some …
us
(code pays fourni par la source)
2023
conference-abstract
OpenAlex
Ellen Nguyen, Shiker Nair, John F. Davis, Antonella Masciotti et autres
Abstract Our multiplexed cell viability platform, PRISM (profiling relative inhibition simultaneously in mixtures), enables screening of potential cancer therapeutics at an unprecedented scale. We routinely assess the effects of perturbations against more than 900 cancer cell lines concurrently through the use of …
us
(code pays fourni par la source)